Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.57 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | FPR3 | P25089 | 2/20 | 0.47 |
| ▸ | FPR2 | P25090 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799688 | 0.91 | ABL1 (0.67) | ABL1METCYP3A4NPC1RAB9A | |
| SCHEMBL613934 | 0.90 | ABL1 (0.69) | ABL1METCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL2804550 | 0.84 | ABL1 (0.53) | ABL1METCYP3A4NPC1RAB9A | |
| SCHEMBL3404307 | 0.83 | MET (0.54) | ABL1PRMT3METCYP3A4 | |
| SCHEMBL23900995 | 0.80 | ABL1 (0.66) | ABL1METCYP3A4NPC1RAB9A | |
| SCHEMBL543789 | 0.80 | ABL1 (0.69) | ABL1METCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL544953 | 0.79 | ABL1 (0.55) | ABL1METCYP3A4NPC1RAB9A | |
| SCHEMBL23901243 | 0.79 | ABL1 (0.64) | ABL1METCYP3A4NPC1RAB9A | |
| SCHEMBL6068329 | 0.79 | GSK3B (0.55) | ABL1PRMT3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6067899 | 0.77 | ABL1 (0.62) | ABL1METCYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321777-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2016-04-26 | — | — | US | claimed |
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2015-12-03 | — | — | US | claimed |
| US-8546393-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2013-10-01 | — | — | US | claimed |
| US-9321777-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2015-12-03 | — | — | US | disclosed |
| US-9115134-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI (FR) | 2014-01-02 | — | — | US | disclosed |
| US-8546393-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| EP-2178881-A2 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | Sanofi-Aventis (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009056692-A2 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | ABL1 8/4885PRMT3 304/4885MET 1/4885 |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | ABL1 8/4885PRMT3 304/4885MET 1/4885 |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | BMX, MET, TPMT | ABL1 20/4885PRMT3 603/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.